This analysis finds that 57.4 million adults under the age of 65 could potentially be eligible for GLP-1 drugs based on currently approved FDA indications, including 36.2 million people with obesity.About 42% of those with commercial insurance could be eligible for glucagon-like peptide 1 (GLP-1) drugs used to treat people with type 2 diabetes, obesity, […]
